Skip to main content
. 2020 Mar 25;21:137–149. doi: 10.1016/j.jor.2020.03.016

Table 1.

Included studies reporting on outcomes following viscosupplementation.

Study Summary HA Dosing Cohort Size Arthritis Grade Follow-Up Period Variables
De Lucia et al. 201948 HMW-HA vs. MMW-HA vs. Controls HMW (x3) vs. MMW (x3) HMW: n = 43, MMW: n = 79, Controls: n = 20 KL II-IV 1-month
6-months
12-months
24-months		 VAS
WOMAC Total, Pain, Function
Brander et al. 201949 HA vs. NS Hylan G-F 20 (x1) HA: n = 182; Saline: n = 175 KL II-III 26-weeks WOMAC Total
Patient Global Self-Assessment
Clementi et al. 201819 UHMW-HA vs. MMW-HA Fermathron S (1x), Hyalubrix 60 (1x) UHMW: n = 23; MMW: n = 27 KL III 1-month
3-month
6-month
12-month		 Lequesne Index
VAS
WOMAC Pain, Function
Suppan et al. 201754 HA vs. HA GO-ON (1x vs. 3x) Single: n = 63; Triple: n = 64 KL I-III 3-months WOMAC Total
Doria et al. 201735 HA vs. PRP Hyalubrix (x3) HA: n = 40;
PRP: n = 40		 KL 0-II 6-months
12-months		 WOMAC Pain, Function
VAS
HHS
Mauro et al. 201720 HA (Hyalubrix) + exercise therapy Hyalubrix (x3) n = 40 KL II-IV 10-weeks VAS
Lequesne Index
Migliore et al. 201721 HA HyalOne/Hyalubrix (x1) n = 1,022 KL I-IV Every 6-months for 7-years Lequesne Index
VAS
Patient Global Self-Assessment
Abate et al. 201722 LMW + HMW-HA vs. HMW-HA LMW + HMW (x1), HMW (x1) LMW + HMW: n = 20; HMW: n = 20 KL II-IV 3-months
6-months		 Lequesne Index
HHS
VAS
Eymard et al. 201753 HA HAnox-M-XL (1x) n = 90 KL I-IV 3-months WOMAC Pain, Function
Patient Global Self-Assessment
Di Sante et al. 201636 HA vs. PRP Na-HA (x3) HA: n = 22; PRP: n = 21 KL II-III 1-month
4-months		 VAS
WOMAC Pain, Function
Dallari et al. 201637 HA vs. PRP vs. HA + PRP Hyalubrix (x3) HA: n = 36; PRP: n = 44; PRP + HA: n = 31 KL I-IV 2-months
6-months
12-months		 VAS
HHS
WOMAC Total
Battaglia et al. 201338 HA vs. PRP Hyalubrix (x3) HA: n = 50; PRP: n = 50 KL II-IV 1-month
3-month
6-month
12-month		 VAS
HHS
Migliore et al. 201261 HA HyalOne (x1) n = 176 KL I-IV 24-months
48-months		 THA Rates
Migliore et al. 201262 HA Hylan G-F 20 (x1) n = 224 KL I-IV 12-months
24-months
5-years		 THA Rates
Migliore et al. 201123 HA HyalOne (x1) n = 120 KL I-IV 3-month intervals up to 18-months VAS
Lequesne Index
Atchia et al. 201150 HA vs. No Injection vs. NS vs. Corticosteroid Durolane (x1) HA: n = 19; NS: n = 19; Corticosteroid: n = 20; No Injection: n = 20 Croft 1–2 or 3-4 1-week
1-month
2-months		 WOMAC Pain, Function
Spitzer et al. 201051 HA vs. Methylprednisolone Hylan G-F 20 (x2) HA: n = 150; MPA: n = 155 KL II-III 1-month
2-months
3-months
4-months
5-months
26-weeks		 WOMAC Total, Pain, Function
Patient Global Self-Assessment
Eyigor et al. 201024 HA Adant (x3) n = 21 KL III-IV 1-month
3-month
6-months		 VAS
Lequesne Index
Migliore et al. 200925 HA Hylan G-F 20 (x1) n = 78 KL I-IV 3-months
6-months
9-months
12-months		 VAS
Lequesne Index
Dıraçoğlu et al. 200939 HA N/A (x3) n = 19 KL I-II 1-month VAS
WOMAC Total, Pain, Function
Conrozier et al. 200926 HA NASHA (x1) n = 34 KL I-IV Mean: 159 days (range: 60–180) Patient Global Self-Assessment
VAS
WOMAC Pain, Function
Lequesne Index
Richette et al. 200940 HA vs. Placebo Adant (x1) HA: n = 42; Placebo: n = 43 KL II-III 3-months VAS
WOMAC Total, Pain, Function
Patient Global Self-Assessment
Migliore et al. 200927 HA vs. Anaesthetic Hyalubrix (x1) HA: n = 22; Anaesthetic: n = 20 KL II-IV 3-months
6-months		 VAS
Lequesne Index
Patient Global Self-Assessment
Migliore et al. 200828 HA Hylan G-F 20 (x1-x3) n = 250 KL II-III 3-months
6-months
9-months
12-months		 VAS
Lequesne Index
Patient Global Self-Assessment
Van Den Bekerom et al. 200841 HA Formulations (Adant, Synocrom, Synvisc) Adant (x1), Synocrom (x1), Synvisc (x1) Adant: n = 91; Synocrom: n = 20; Synvisc: n = 15 N/A 6-weeks VAS
HHS
THA rates
Gaston et al. 200755 HA Suplasyn (x3) n = 15 Mean: 2.7 ± 0.88 3-months
6-months		 HHS
Conrozier et al. 200642 HA Hylan G-F 20 (x1/x2) n = 56 KL II-III 3-months WOMAC Pain, Function
Patient Global Self-Assessment
VAS
Van Den Bekerom et al. 200643 HA Formulations Orthovisc (x1-x3), Synvisc (x1-x3), Fermatron (x1-x3) n = 60 N/A 6-weeks VAS
THA rates
Migliore et al. 200529 HA Hylan G-F 20 (x1) n = 30 KL I-III 2-months
6-months		 Lequesne Index
VAS
Qvistgaard et al. 200644 HA vs. NS vs. Corticosteroid Hyalgan (x3) HA: n = 33; NS: n = 36; Corticosteroid: n = 32 KL I-II or III-IV 2-weeks
4-weeks
3-months		 VAS
Migliore et al. 200530 HA Hyalgan (x2) n = 14 KL II-IV 3-months
6-months
9-months
12-months		 VAS
Lequesne Index
Patient Global Self-Assessment
Pourbagher et al. 200545 HA Na-hyaluronate (x3) n = 10 Hartofilakidis I-II 2-months
4-months
6-months		 VAS
WOMAC Total
Tikiz et al. 200531 HA Formulations Hylan G-F 20 (x3), Na-hyaluronate (x3) Hylan G-F 20 (n = 18) vs. Na-Hyaluronte (n = 25) KL 1-III 1-month
3-months
6-months		 VAS
WOMAC Total
Lequesne Index
Migliore et al. 200532 HA Hylan G-F 20 (x1) n = 12 KL I-II or III-IV 1-month
3-month		 VAS
Lequesne Index
Caglar-Yagci et al. 200533 HA Hylan G-F 20 (x3) n = 14 KL I-III 1-month
3-months		 VAS
Lequesne Index
Berg et al. 200452 HA NASHA (x1) n = 31 KL II-III 2-weeks
3-months		 WOMAC Pain, Function
Patient Global Self-Assessment
Conrozier et al. 200346 HA Hylan G-F 20 (x1/x2) n = 57 KL II-III 3-months VAS
WOMAC Total, Pain, Function
Patient Global Self-Assessment
Vad et al. 200347 HA Hylan G-F 20 (x3) n = 22 N/A 12-months VAS
Brocq et al. 200234 HA Hylan G-F 20 (x1/x2) n = 22 KL I-III 1-week
1-months
2-months
3-months
6-months		 VAS
Lequesne Index

HA: Hyaluronic Acid; PRP: Platelet-Rich Plasma; NS: Normal Saline; UHMW: Ultra High Molecular Weight; HMW: High Molecular Weight; MMW: Medium Molecular Weight; LMW: Low Molecular Weight; THA: total hip arthroplasty; VAS: visual analog scale; HHS: Harris Hip Score; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; N/A: Information Not Available; KL: Kellgren-Lawrence.